Gilead Acquires Experimental Inflammation Drug in $1.3 Billion Deal
On October 22, pharmaceutical giant, Gilead Sciences, acquired PepStar Therapeutics’ oral inflammation drug program in a deal worth $1.275 billion in upfront cash. A primary drug involved in the agreement is HCXT-2001, an experimental treatment that is currently undergoing Phase 1 clinical trials. This acquisition marks another step in Gilead’s expansion beyond its core HIV business.
HCXT-2001 targets the interleukin-23 (IL-23) receptor, which regulates immune responses associated with inflammatory conditions such as psoriasis, Crohn's disease, and ulcerative colitis. There is massive financial opportunity in the market for IL-23 treatments as current therapies like Abbvie’s Skyrizi have already shown huge commercial success. Skyrizi, specifically, generated almost $10 million in revenue in the first half of 2026 alone.
But HCXT-2001 isn’t the same as the other treatments currently available. Rather than requiring the injections or intravenous infusions that established therapies need, HCXT-2001 is administered orally. In addition, the pill contains an extended half life, potentially lowering the amount of dosages patients need to take. Together, the pill offers greater convenience for its consumers and differentiates itself from competing solutions.
Despite its commercial potential, HCXT-2001 remains in Phase 1 trials where it is being tested for safety and tolerability. Its effectiveness for treating inflammatory diseases has not been established yet either. Gilead’s $1.3 billion therefore represents a huge financial risk. Unlike acquisitions structured around milestone payments, much of the investment is committed before the drug demonstrates clinical success.
Nevertheless, the acquisition could help Gilead Sciences create new revenue streams. As it is primarily an HIV business with HIV sales still increasing 18% year over year in the third quarter of 2026, expanding into immunology could provide additional long-term growth opportunities and help it diverge from relying solely on a few existing treatments.
Of course, HCXT-2001 faces many challenges before being able to produce any revenue for Gilead as it must successfully complete clinical trials, secure regulatory approval, and compete against established products. Yet the acquisition reflects how aggressively pharmaceutical companies are investing in promising early-stage biotechnology. Gilead is betting that the clinical advantages of HCXT-2001 will propel it to success that will justify its substantial acquisition cost.
